LEX Diagnostics

Based in the United Kingdom, LEX Diagnostics is a startup. LEX Diagnostics has been acquired. Brouky classifies it under Healthcare & Life Sciences.

LEX Diagnostics developed the NULEXA ultra-fast multiplex PCR point-of-care system that rapidly detects and differentiates respiratory pathogens including Influenza A/B and SARS-CoV-2, delivering fully automated swab-to-result diagnostics in under 10 minutes with CLIA-waived approval for use in physician offices, pharmacies, and urgent care facilities.